Oppenheimer raised the firm’s price target on Guardian Pharmacy (GRDN) to $35 from $30 and keeps an Outperform rating on the shares following quarterly results. Overall, the results were solid, as Guardian continues a methodical approach to growth that unlocks attractive value over time, the firm says.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN: